trial summary · NCT07213960
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis
Trial record from the TrialBase DB dataset, status RECRUITING, condition FSGS, sponsored by Apellis Pharmaceuticals, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.
Source record: https://clinicaltrials.gov/study/NCT07213960
Facts
| registry id | NCT07213960 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2/PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | FSGS |
| sponsor | Apellis Pharmaceuticals, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 270 |
| start date | 2026-12 |
| primary completion | 2029-10 |
| completion | 2029-12 |
| results posted | not reported |
Conditions
- FSGS
Interventions
- APL2
- Placebo
Countries
- United States
Intervention types: DRUG, OTHER
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.